Arabic Arabic English English French French German German
dark

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease

Treatment with BIIB122/DNL151 achieved robust reductions in biomarkers of target engagement and pathway engagement in healthy volunteers and patients with Parkinson’s disease Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Cytoprotective effect of eckol against oxidative stress-induced mitochondrial dysfunction.

Next Post

Statement from the Chief Public Health Officer of Canada on May 1, 2021

Related Posts
Total
0
Share